2025-11-06 - Analysis Report
Okay, let's analyze MRK (Merck & Co Inc) based on the provided data. I'll present the data with key numbers first, followed by a summary and analysis.

**Report: Merck & Co. (MRK) Analysis**

**0) Summary of Key Numbers**

*   **Ticker:** MRK
*   **Company:** Merck & Co Inc.
*   **Current Price:** $84.36
*   **5-Day Moving Average:** $85.14
*   **20-Day Moving Average:** $85.94
*   **60-Day Moving Average:** $84.46
*   **RSI:** 51.01
*   **PPO:** -0.515
*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **Analyst Consensus:** Buy (Mean: 2.04)
*   **Target Price (Avg):** $101.54

**1) Performance vs. S&P 500 (VOO)**

*   **MRK Cumulative Return:** -0.25%
*   **VOO Cumulative Return:** 99.52%
*   **Performance Difference:** -101.5%
*   **Relative Performance Deviation:** 1.9

**Analysis:**

Merck & Co Inc. is a global pharmaceutical company.

MRK has significantly underperformed the S&P 500 (VOO) over the period examined. The cumulative return difference is a substantial -101.5%.  The "Relative Deviation" of 1.9 suggests MRK's underperformance is near the lower end of its historical range relative to the S&P 500.

**Alpha/Beta Analysis:**

| Year       | CAGR     | MDD   | Alpha    | Beta   | Cap(B) |
|------------|----------|-------|----------|--------|--------|
| 2015-2017  | 1.0%     | 68.5% | -28.0%   | 0.0    | 134.2  |
| 2016-2018  | 36.0%    | 69.8% | 21.0%    | -0.0   | 182.2  |
| 2017-2019  | 40.0%    | 69.8% | 18.0%    | 0.3    | 216.8  |
| 2018-2020  | 16.0%    | 79.6% | -8.0%    | 0.3    | 195.0  |
| 2019-2021  | 2.0%     | 79.6% | -44.0%   | 0.7    | 191.5  |
| 2020-2022  | 15.0%    | 79.6% | 16.0%    | 0.7    | 277.2  |
| 2021-2023  | 33.0%    | 79.6% | 31.0%    | 0.3    | 272.4  |
| 2022-2024  | -4.0%    | 79.6% | -25.0%   | 0.2    | 248.6  |
| 2023-2025  | -50.0%   | 71.5% | -114.0%  | 1.7    | 210.8  |

**Analysis:**

*   **CAGR:** The Compound Annual Growth Rate varies significantly across different periods, with a recent steep decline.
*   **MDD:** Maximum Drawdown is consistently high, indicating substantial risk and volatility.
*   **Alpha:** Alpha fluctuates, showing periods of both outperformance and underperformance relative to the market.  Recent years show significantly negative alpha, indicating substantial underperformance.
*   **Beta:** Beta values are relatively low, suggesting MRK's price is not highly correlated with the overall market. However, the recent Beta of 1.7 in 2023-2025 suggest high volatility.
*   **Cap(B):**  The Market Capitalization (in Billions) shows growth over the period, but with recent declines, corresponding with decline in price, showing current company's weakness.

**2) Recent Price Action**

*   **Current Price:** $84.36
*   **Last Market Data:** Price: $84.40, Previous Close: $83.86, Change: $0.64 (slight increase)
*   **5-Day Moving Average:** $85.14
*   **20-Day Moving Average:** $85.94
*   **60-Day Moving Average:** $84.46

**Analysis:**

The current price is slightly below the 5-day and 20-day moving averages, suggesting a short-term downtrend.  The price is near the 60-day moving average. The small increase in the last market data suggests a slight rebound, but it's not strong enough to reverse the downtrend.

**3) Technical Indicators and Expected Return**

*   **MRI:** 0.9 (High Investment Recommended) - The Market Risk Indicator suggests that this is a good investment, based on a combination of factors.
*   **RSI:** 51.01 - Neutral, indicating neither overbought nor oversold conditions.
*   **PPO:** -0.515 - Slightly negative, suggesting the short-term moving average is below the long-term moving average.
*   **Hybrid Signal:**  Cash_0%_Buy 100% of cash (206 shares - Very Safe - MRI:0.90)
*   **Recent (20-day) Relative Deviation Change:** -4.7 (Negative) - Indicates a short-term decrease in relative performance.
*   **Expected Return (%):** -409.3% - This is a *very* negative expected return, suggesting significant underperformance relative to the S&P 500 over the long term *if* the model's assumptions hold.

**Analysis:**

While the MRI suggests a "High Investment Recommended," the extremely negative expected return is a major red flag. The negative change in relative deviation reinforces the recent underperformance trend.  The slight price increase compared to the previous close may be a temporary fluctuation.

**4) Recent News & Significant Events**

*   **Positive:** Valuation Insights After Upbeat Q3, Oncology Growth, Quebec Expands Public Funding, Securing Funding for Cancer Asset, No. 1 Drug Claim.
*   **Negative:** Insider Selling

**Analysis:**

The news is mixed. Several articles highlight positive aspects like oncology growth and strategic funding. However, the insider selling is a negative signal.

**4-2) Analyst Opinions**

*   **Consensus:** Buy (2.04)
*   **Target Price:** $101.54 (Avg)

**Analysis:**

Analysts, on average, have a "Buy" rating on MRK and a target price significantly above the current price. This suggests they believe the stock is undervalued.

**5) Recent Earnings Analysis**

| 날짜         | EPS  | 매출       |
|--------------|------|------------|
| 2025-08-05  | 1.76 | 15.81 B$   |
| 2025-05-02  | 2.01 | 15.53 B$   |
| 2024-11-06  | 1.25 | 16.66 B$   |
| 2024-08-05  | 2.15 | 16.11 B$   |
| 2025-08-05  | 2.15 | 16.11 B$   |

**Analysis:**

EPS and revenue have fluctuated. While there are some strong quarters, there is no clear consistent upward trend. Revenue has been relatively stable, but EPS has shown more volatility. The latest EPS data from 2025-08-05 seems lower than historical EPS.

**6) Financial Information**

**Revenue and Profitability:**

| Quarter    | Revenue   | Profit Margin |
|------------|-----------|---------------|
| 2025-06-30 | $15.81B   | 77.50%        |
| 2025-03-31 | $15.53B   | 77.98%        |
| 2024-12-31 | $15.62B   | 75.50%        |
| 2024-09-30 | $16.66B   | 75.51%        |
| 2024-06-30 | $16.11B   | 76.76%        |

**Capital and Profitability:**

| Quarter    | Equity    | ROE      |
|------------|-----------|----------|
| 2025-06-30 | $48.99B   | 9.04%    |
| 2025-03-31 | $48.34B   | 10.51%   |
| 2024-12-31 | $46.31B   | 8.08%    |
| 2024-09-30 | $44.50B   | 7.09%    |
| 2024-06-30 | $43.58B   | 12.52%   |

**Analysis:**

*   **Revenue:** Relatively stable revenue over the past five quarters.
*   **Profit Margin:** Consistently high profit margins, indicating strong pricing power.
*   **Equity:** Increasing equity over the period.
*   **ROE:** ROE has fluctuated, with a recent decline.

**7) Comprehensive Analysis and Recommendation**

**Summary:**

MRK has significantly underperformed the S&P 500. Recent price action suggests a short-term downtrend. While the MRI indicates a high investment recommendation and analysts have a "Buy" rating, the extremely negative expected return (-409.3%) is concerning.  Revenue and profit margins are strong, but EPS and ROE have fluctuated. Insider selling is a negative signal.

**Recommendation:**

Despite the positive analyst ratings and high MRI, the negative expected return and recent underperformance are significant concerns.  The mixed news flow and short-term downtrend suggest caution.

**Therefore, a "Hold" or "Cautious Watch" recommendation is warranted.  Further investigation into the reasons behind the negative expected return and the recent underperformance is necessary before considering a "Buy" position.**

**Further Considerations:**

*   Investigate the drivers behind the negative expected return. Is it related to specific drug pipelines, market competition, or other factors?
*   Monitor future earnings reports and news flow for signs of improvement or further deterioration.
*   Consider the overall market conditions and the healthcare sector outlook.

This analysis is based solely on the provided data and does not constitute financial advice. Consult with a qualified financial advisor before making any investment decisions.
